|Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion |
|Jena, July 15, 2020 |
In view of the continuing Covid-19 pandemic and its impact on relevant markets, Carl Zeiss Meditec AG (ISIN: DE0005313704) expects to see a further impact on business development in the remainder of fiscal year 2019/20 compared to previous year.
Assuming a recovery in markets and, in particular, that no significant additional measures to contain the Covid-19 pandemic will impact development, management anticipates revenue of around EUR 1.3 billion for fiscal year 2019/20 (previous year EUR 1.459 billion).
In the first nine months of fiscal year 2019/20, Carl Zeiss Meditec has achieved revenue of EUR 967.9 million (previous year EUR 1,027.6 million). This corresponds to a decline of 5.8% vs. the previous year. After adjustment for currency effects, the decline amounted to 6.9%.
Earnings before interest and taxes (EBIT) amounted to EUR 111.9 million after the first nine months of 2019/20 (previous year: EUR 184.2 million). Earnings per share (EPS) were EUR 0.77 (previous year: EUR 1.22).
The quarterly statement of the first nine months of fiscal year 2019/20 will be published on August 5, 2020.
Contact for investors and press
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
 Currency-adjusted revenue growth is calculated by converting current period revenue with the exchange rates of the previous year's period.
15-Jul-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de